Wegovy prescribing information sheet The information referred to may not comply with Australian regulatory requirements. After 28 days, Wegovy should no longer be used, even if you put 2 Information about semaglutide . These highlights do not include all the information needed to use Aranesp safely and effectively. To ensure you receive the information that meets your needs, please tell us whether you are: I am a member of the public based in GB → I am a patient prescribed Wegovy ® in GB → Semaglutide (Wegovy) is a type of medicine that can be used for aiding weight loss in adults and children over 12 years. 25 to 2. 25 mg once a week, and you will gradually increase your dose every four weeks. • • RECENT MAJOR Refer to Instructions for Use within the Prescribing Information for how to use the Wegovy® pen. Wegovy ® contains semaglutide and should not be used with other semaglutide-containing products or other GLP-1 receptor agonist medicines. Tell your health care professional if you have any Suitable for prescribing in primary care following recommendation or initiation by a specialist. 4 mg is indicated for chronic weight management for adults with obesity and to reduce the risk of major adverse cardiovascular events in adults with obesity or overweight and cardiovascular disease. Includes: indications, dosage, adverse reactions and pharmacology. It is not known if Wegovy ® is safe and effective for use in children under 12 years of age. Wegovy® is marketed and indicated for obesity. Find out side effects, medicine names, dosages and uses. 5mg weekly; Week 9 to week 12: 1mg weekly; Week 13 to week 16: What to know about prescribing Wegovy™ How to prescribe once-weekly Wegovy™ Wegovy™ comes in 5 packs (one for each strength). • Wegovy-pi-v2. Each pack contains 4 Wegovy™ pens (one pen for each week). 25 or 0. This is the Product Information that was approved with the submission described in this AusPAR. In studies with rodents, Wegovy® and medicines that work like Wegovy® caused thyroid tumors, including thyroid cancer. Wegovy 0. Wegovy® FlexTouch® Consumer Medicine Information 1 Wegovy® FlexTouch® Consumer Medicine Information (CMI) summary The full CMI on the next page has more details. Semaglutide (Wegovy, Novo Nordisk) is 'indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of ≥30 kg/m. It is not known if Wegovy™ will cause thyroid tumors or a type of thyroid cancer called Administer WEGOVY once weekly as an adjunct to diet and increased physical activity, on the same day each week, at any time of day, with or without meals (2. Weeks 5 through 8 = 0. In clinical trials, Wegovy users achieved an average weight loss of 14. After a 3-month (12-week) screening period in which each participant received behavioral lifestyle therapy (counseling about healthy nutrition and physical activity), participants were then randomly assigned to two groups. The injection site Wegovy ® (semaglutide injection) Product Monograph Page 4 of 64 . Created Date: 12/13/2023 10:35:37 PM The Department of Health and Social Care have produced some public facing information on accessing semaglutide for weight loss: Accessing Wegovy for weight loss: Everything you need to know. Signal Word Not required Hazard These highlights do not include all the information needed to use WEGOVY safely and effectively. It acts in the same way as GLP-1 (a natural hormone in the body) and, among other things, appears to regulate appetite by increasing a person Count on your Health Coach. Wegovy is to be injected subcutaneously in the abdomen, in the thigh or in the upper arm. Patient may need a regular review, but this would not exceed that required for other medicines routinely prescribed in primary care. Search the Exchange To access the Prescribing Information for Novo Nordisk products, please explore our product page. Approval: 2017 Wegovy (Semaglutide 0. In studies with rodents, Wegovy™ and medicines that work like Wegovy™ caused thyroid tumors, including thyroid cancer. I am a member of the public based in GB →. See full prescribing information for WEGOVY®. Change (i. 4 weekly. ; Wegovy is generally safe for HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use WEGOVY® safely and effectively. 5 mg once weekly. For the most up to date information, consult the summary of product characteristics For information on Bedfordshire and Luton Joint Prescribing Committee (JPC) recommendations on Wegovy package insert / prescribing information for healthcare professionals. Do not use Wegovy™ if particulate matter or colouration is seen. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment. Your Coach can help you: Get off to a good start with Wegovy ® by offering guidance and sharing tips; Find information about insurance coverage and Wegovy ® savings ; Set achievable goals and take Scroll to ISI What is Wegovy ®?. It has the smallest size and Please see additional Important Safety Information throughout. They all advised the same thing: diet and exercise. The injection site Wegovy™ solution should be inspected visually prior to each injection and should be clear, colourless, and contain no particles. Wegovy ® (semaglutide) injection 2. to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight The most common side effects of Wegovy ® may include nausea, diarrhea, vomiting, constipation, stomach (abdomen) pain, headache, tiredness (fatigue), upset stomach, dizziness, feeling bloated, belching, low blood sugar in people with type 2 diabetes, gas, stomach flu, heartburn, and runny nose or sore throat. 7 mg • n I your fifth month, you’ll increase your weekly dose to 2. Sponsor. If needed, prior to cap removal, the pen can be kept from 8°C to 30°C (46°F to 86°F) up to 28 days. 4 mg. • • RECENT MAJOR Revised: September 13, 2024 Wegovy Prior Authorization Form Fax completed form to MedStar Family Choice-MD 1-888-243-1790 or 410-933-2274 ALL requests must be accompanied by MEDICAL RECORDS to support the request. 31 March 2021. 25 March 2022. See full prescribing information for MOUNJARO. WARNING: ESAs INCREASE THE RISK OF DEATH, Wegovy Prescribing Information. WEGOVY ® (semaglutide) injection 2. Published. Recommended Dosage in Pediatric Patients Aged 12 Years and Older Dosage Initiation and Escalation Initiate WEGOVY according to the dosage escalation schedule in Table 2 to minimize gastrointestinal adverse reactions . Unlike all other GLP-1 analogs, Semaglutide is 94% identical to the natural endogenous GLP-1. NAME OF THE MEDICINAL PRODUCT . Further information relevant to the Australian environment is available from Novo Nordisk (Australia) or via What is the most important information I should know about Wegovy®? (cont’d) Wegovy® may cause serious side effects, including: (cont'd) •Do not use Wegovy® if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine were randomized to receive either Wegovy™ (reduced calorie meal plan and increased physical activity) or placebo (reduced calorie meal plan and increased physical activity only), and evaluated over a 68-week period. Please see additional Important Safety Information throughout. solution for injection in pre-filled pen . This video is based on the Instructions for Use that come with your Wegovy ® pen. wegovy FlexTouch . Administer WEGOVY once weekly as an adjunct to diet and increased physical activity, on the same day each week, at any time of day, with or without meals (2. Brief prescribing document or information sheet may be required. Wegovy should Wegovy ® (semaglutide) injection 2. Talk to your These highlights do not include all the information needed to use WEGOVY safely and effectively. Wegovy 1 mg solution for injection in pre-filled pen . March 2024. Dosing with Wegovy™ • Start Wegovy™ with a dose of 0. It is not known if Wegovy® (semaglutide) will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people. • 1. Administer Wegovy™ subcutaneously in the abdomen, thigh, or upper arm. The starting Wegovy dose is 0. Costing information Based on the NICE Resource Impact Template for NICE TA875, the estimated cost of implementing this guidance is HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use WEGOVY® safely and effectively. Denmark: Wegovy was made available in Denmark, and all dose strengths were accessible since a specific time. Wegovy Recommended Dosage. Your health care provider can select either 1. Important Safety Information What are the possible side effects of Wegovy®? (cont’d) Wegovy® may cause serious side effects, including: (cont’d) • kidney problems (kidney failure). WEGOVY® (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced-calorie diet and increased physical activity: WARNING: RISK OF THYROID C-CELL TUMORS See full prescribing information for complete boxed warning. 25 mg per week; Escalate the patient’s Wegovy ® dose every 4 weeks; Please refer to the Prescribing Information for full dosing information; If patients do not tolerate a dose during dose escalation, consider delaying dose escalation for 4 weeks HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use WEGOVY® safely and effectively. Wegovy: Start with 0. This will allow quick identification of new safety information. Initiate Wegovy with a dose of 0. Wegovy ® 1. References to depression and suicidal thoughts have not substantially changed. 1 1 1 2-6 2 3 4 with Overweight or Obesity 5 6 3 3 1 1. The Wegovy shortage poses significant challenges for healthcare providers trying to manage their patients' weight loss and health. Attachment Product Information for Wegovy [PDF, 1018. Date registered. Read about dosing, administration, pen storage and get details on benefits FULL PRESCRIBING INFORMATION . HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use WEGOVY safely and effectively. Gastrointestinal disorders were the most frequent adverse events with Wegovy ® (62% vs 42% with placebo); 2. If you have any questions about your prescription please contact your prescriber. C. Approval: 2017 WARNING: RISK OF THYROID C−CELL TUMORS See full prescribing information for FULL PRESCRIBING INFORMATION . 7-clean Page 1 of 29 AusPAR - Wegovy - semaglutide - PM-2021-00612-1-5 - Novo Nordisk Pty Ltd Date of Finalisation 4 September 2024. Marketing authorisation indication . com or phone 1800 668 626. Healthcare professionals are asked to report any suspected adverse reactions. It is not known if Wegovy ® will cause thyroid tumors or a type of thyroid cancer called medullary thyroid What is Wegovy ®?. wegovy - Free download as PDF File (. 25 mg FlexTouch® solution for injection in pre-filled pen . Approval: 2017 Scroll to ISI What is Wegovy ®?. [1] The active ingredient in Wegovy® is semaglutide, a glucagon-like peptide 1 receptor agonist that is more commonly known as a GLP-1 medication. The injection site can be changed without dose adjustment. Below is an example of a dosing schedule. OZEMPIC (semaglutide) injection, for This guide will help you: Learn how to use your pen Understand the dosing schedule Know what to expect Access support and savings Your next step begins here Scroll to ISI What is Wegovy ®?. Initiate at 0. 2020; 28:1050-1061. semaglutide . 0. 5 mL 1 mg/0. 1 September 2022. com, you can edit, sign, share, and download the Wegovy Medication Information for Safe Use along with hundreds of thousands of other documents. Instructions for use Administer WEGOVY once weekly as an adjunct to diet and increased physical activity, on the same day each week, at any time of day, with or without meals (2. Wegovy™ solution should be inspected visually prior to each injection and should be clear, colourless, and contain no particles. wegovy is a medicine for weight loss and weight maintenance that contains the active substance semaglutide. In rodents, semaglutide causes thyroid C-cell tumors Indications and Usage. As these instructions illustrate, the recommended storage temperature for Wegovy is between 36°F and 46°F (2°C and 8°C). Wegovy™ (semaglutide) injection 2. 0%) Wegovy ®-treated patients were between 65 and 74 years of age and 23 (1%) were ≥ 75 years of age. 4 mg for your maintenance dose. along with diet and exercise to improve blood sugar (glucose) in adults with type 2 diabetes; to This video is based on the Instructions for Use that come with your Wegovy ® pen. to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight Please see additional Important Safety Information throughout. Wegovy has become one of the most popular FDA-approved treatments for weight management. I continued to diet and lose weight and gain it back. Consider treatment response and tolerability when selecting the maintenance dose This information from Lexicomp explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider. 5 mL 0. Saxenda ® should be inspected for changes such as precipitation, or change in color or clarity that may indicate a Suitable for prescribing in primary care following recommendation or initiation by a specialist. Wegovy® works by causing you to feel fuller and less hungry. pdf), Text File (. Do not use Wegovy™ if particulate matter or colouration Wegovy is administered once weekly at any time of the day, with or without meals. Renewal PA requests require the member to be taking an appropriate maintenance dose, as outlined in the Wegovy prescribing information. See full prescribing information for RYBELSUS. Inject subcutaneously in the abdomen, thigh or upper arm (2. Read this Instructions for Use before you start using WEGOVY. Wegovy® 1 mg FlexTouch® solution for injection in pre-filled pen . PAY $25 *Eligibility and restrictions apply. Initial U. Wegovy. You can help by reporting any side effects you may get. OSHA Hazcom 2012 and Canadian WHMIS 2015 regulations. Plainsboro, NJ. 4 mg is indicated in combination with a reduced calorie diet and increased physical activity:. 17 KB] Device/Product Name. 4 mg, along with a reduced calorie diet and increased physical activity, is used to reduce the risk of major cardiovascular (CV) events such as death, heart attack, or stroke in This website has been developed by Novo Nordisk UK to provide information about: Wegovy ® (semaglutide injection) for Great Britain (GB). How does Wegovy work? The active substance in Wegovy, semaglutide, is a ‘GLP-1 receptor agonist’. See full prescribing information for complete boxed warning. 5 mg/0. 4 mg is an injectable prescription medicine that may help adults with obesity (BMI ≥30) or some adults with excess weight (BMI ≥27) These highlights do not include all the information needed to use WEGOVY safely and effectively. Approval: 2001 . Continue reading Scroll to ISI What is Wegovy ®?. If patients do not tolerate a dose during dosage escalation, consider delaying dosage escalation for 4 weeks. Wegovy ® Semaglutide . 4 September 2024. Serious Warnings and Precautions The effect of Wegovy ® 2. Approval: 2017 WARNING: RISK OF THYROID C−CELL TUMORS See full prescribing information for Abbreviated prescribing information . These challenges include: Treatment disruptions: The shortage can disrupt treatment plans, leaving healthcare providers with limited options for prescribing Wegovy to their patients. Wegovy is administered once weekly at any time of the day, with or without meals. · Your WEGOVY pen is for 1 time use only. 4 mg once weekly. 1)]: • 230 kg/m or greater (obesity) or These highlights do not include all the information needed to use WEGOVY ® safely and effectively. 4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. 4 mg weekly) Information Sheet What is Wegovy? Wegovy (semaglutide) is a prescription medicine that helps adults who are overweight or have obesity to manage their weight. Wegovy ® (semaglutide injection) is wegovy is used in addition to diet and physical activity to reduce the risk of serious heart issues (heart-related death, heart attacks, strokes) in adults with a history of heart disease (like a Wegovy-pi-v0. 9% over 68 weeks, significantly higher than the 2. Store the Wegovy single-dose pen in the refrigerator from 2°C to 8°C (36°F to 46°F). 25 mg once These highlights do not include all the information needed to use OZEMPIC ® safely and effectively. Semaglutide 2. 1). 5 years (41. 4 mg once-weekly dose, the dose can Wegovy is administered by a weekly subcutaneous (SC) injection. What is Wegovy®? Wegovy® (semaglutide) injection 2. If Saxenda ® was exposed to non-refrigerated temperatures (any temperature above 46°F), the product must be used or discarded within 30 days. 3. Ozempic® is marketed and indicated for type 2 diabetes. It is similar to a natural hormone called glucagon-like peptide-1 (GLP-1) that is released from the intestine after a meal. For any product related queries, please contact Novo Nordisk Medical Information on aunrccc@novonordisk. 2 (obesity), or For more information about using Wegovy, see the package leaflet or contact your healthcare provider. Wegovy should Wegovy ® contains the active ingredient semaglutide. ; Long-term results show that 77% of Wegovy users maintained a weight loss of 5% or more after two years, indicating its effectiveness for sustained weight management. 4% loss in the placebo group. Tell your healthcare See the Wegovy ® Prescribing Information for details. If needed, storage between 46°F and 86°F (8°C and 30°C) is permissible for up to 28 days. S Wegovy Fact Sheet UpdatedMar08 7 24 ore fa — 20% relative risk reduction RRR 1 5% absolute ARR * in MACE with Wegovy® as evaluated patients overweight or obesity and to reduce the of major cardiovascular events such death heart Up to date, approved and regulated prescribing and patient information for licensed medicines. 7 mg solution for injection These highlights do not include all the information needed to use WEGOVY safely and effectively. 7 mg or 2. Wegovy ® (semaglutide) injection is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adults with an initial body mass Wegovy is administered once weekly at any time of the day, with or without meals. Please report side effects. Weeks 9 through 12 = 1 mg once weekly. Wegovy® and Ozempic® both contain the same active ingredient, semaglutide. Wegovy® should be used along with a reduced calorie diet and increased physical activity. Click here ®for Prescribing Information, including Boxed Warning, for Saxenda (liraglutide) injection 3 mg. 5 mg solution for injection in pre-filled pen . 2-clean Page 1 of 35 AusPAR - Wegovy - semaglutide - PM-2022-04980-1-5 - Novo Nordisk Pty LtdDate of Finalisation 4 September 2024. Subscribe to updates; Contact us; Facebook (Twitter) Youtube new safety information. Approval: 2017 WARNING: RISK OF THYROID C−CELL TUMORS See full prescribing information for Over 1 year and 4 months (68 weeks), a medical study looked at the effect and safety of Wegovy ® in adolescents with obesity. 25 mg/0. See full prescribing information for WEGOVY. Other information about Wegovy Wegovy received a marketing authorisation valid throughout the EU on 6 January 2022. Individual results may vary. 25 mg once a week for four weeks, and then your Wegovy dose will increase every 4 weeks until you reach a maintenance dose of 1. Approval: 2017 WARNING: RISK OF THYROID C−CELL TUMORS See full prescribing information for HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use WEGOVY® safely and effectively. AusPAR Date. Approval: 2017 WARNING: RISK OF THYROID C−CELL TUMORS See full prescribing information for Prescribing Information & Safety Data Sheets Submit a Question Search the Exchange. . 7 mg once weekly. Authorised Prescriber; Office of Drug Control; State and territory contacts; Connect with us. e. 5 mL 1. 25 mg once weekly for 4 weeks. to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight. Approval: 2017 WARNING: RISK OF THYROID C−CELL TUMORS See full prescribing information for HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use OZEMPIC® safely and effectively. Suspected side effects reported with Wegovy are carefully evaluated and any necessary action taken to protect patients. WARNING: RISK OF THYROID C-CELL TUMORS . Approval: 2017 WARNING: RISK OF THYROID C-CELL TUMORS See full prescribing information for complete boxed warning. Week 1 to week 4: 0. 25 mg (the dose you received in this kit) once per week in your first month • In your second month, increase your weekly dose to 0. Wegovy Dosing Information. In other words, Wegovy is a high-dose injectable Semaglutide, like Ozempic, that is administered weekly. It has gained attention for its ability to support lasting weight loss when combined with a healthy diet and regular exercise. Approval: 2017 WARNING: RISK OF THYROID C−CELL TUMORS See full prescribing information for complete boxed warning. (4). 25mg weekly; Week 5 to week 8: 0. HIGHLIGHTS OF PRESCRIBING INFORMATION . Please see the full Prescribing Information for . WEGOVY (semaglutide) injection, for subcutaneous use . Week 17 and onward = 2. NovoSeven ® RT Ozempic ® Rebinyn ® Rivfloza ® Rybelsus ® Saxenda ® Sogroya ® Tresiba ® Tretten ® Vagifem ® Victoza ® Wegovy Saxenda ® can be used as long as the product has not been exposed to temperatures below 36°F or above 86°F. WEGOVY. 4mg) for overweight and obesity. WEGOVY semaglutide injection, for subcutaneous use Initial U. Our platform helps you seamlessly edit PDFs and other documents online. 1 . to reduce the risk of major adverse cardiovascular events (cardiovascular Indications and Usage. It must be completed by a prescriber for coverage through the TRICARE pharmacy program. PharmaCare's drug coverage decision for semaglutide \(Wegovy\) Keywords These highlights do not include all the information needed to use WEGOVY safely and effectively. Approval: 2017 . It is available as an injection. If needed, however, Wegovy ® can be kept outside of the refrigerator between 46 °F to 86 °F for Indications and Usage. Wilding JP, Batterham R, et al. On average, adults were in the trial for 3. In SELECT, the Cardiovascular Outcomes Trial (CVOT) , 2656 (30%) Wegovy ®-treated patients were between 65 and 74 years of age, and 703 (8. OZEMPIC(semaglutide) injection, for subcutaneous use Initial U. 1. Medicine information. 2 beats per minute from baseline were observed with patients taking Wegovy ® Cardiovascular Risk Reduction . How does Wegovy® work? Wegovy® is similar to a natural hormone called glucagonlike peptide- -1 (GLP-1) that is released from the intestine after a meal. 25 mg, 0. It is to be injected subcutaneously in the abdomen, in the thigh or in the upper arm. 25 mg solution for injection in pre-filled pen . Please talk with your doctor to find out your specific dosing schedule. What is the most important information I should know about WEGOVY? WEGOVY may cause serious side effects, including: • Possible thyroid tumors, including cancer. It may have been superseded. As for all medicines, data on the use of Wegovy are continuously monitored. 2021. Wegovy® is an injectable prescription drug that is FDA-approved and clinically proven to help with weight loss. Wegovy 1. This information does not replace talking to your healthcare provider about your medical condition or treatment. Approval: 2022 WARNING: RISK OF THYROID C-CELL TUMORS See full prescribing information for complete boxed warning. All study participants also received standard of care for their The Prior Authorization Fax Cover Sheet is available on the Forms page of the Portal for prescribers or their designee submitting the forms and documentation by fax. WARNING: RISK OF THYROID C -CELL TUMORS . 1 INDICATIONS AND USAGE WEGOVY is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight WEGOVY is an injectable prescription medicine that may help adults and children aged 12 years and older with obesity, or some adults with excess weight (overweight) who also have weight WEGOVY is indicated in combination with a reduced calorie diet and increased physical activity: • to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal Read Important Safety and Prescribing Info, including Boxed Warning. These highlights do not include all the information needed to use RYBELSUS® safely and effectively. Aranesp® (darbepoetin alfa) injection, for intravenous or subcutaneous use . 4 mg In addition to diet and exercise, to reduce risk of MACE (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CVD and either overweight or obesity, and for chronic weight management in patients with obesity ≥12 years and adults with overweight with at least one weight-related comorbidity. • • RECENT MAJOR In the Wegovy ® phase 3a weight management clinical trials, 233 (9. Note: See the manufacturer’s prescribing information for complete details. 0%) of Wegovy ® Attachment Product Information for Wegovy [Word, 1. If patients do not tolerate a dose during dose escalation, consider delaying dose escalation for 4 weeks; The maintenance dose of Wegovy ® in adults is either 2. This medicine is new or being used differently. Information and fact sheets for patients and professionals. If you are worried about using this medicine, speak to your doctor or pharmacist. Weeks 13 through 16 = 1. 4 mg Prescribing Information. The Wegovy prescribing information sheet posted online was just updated this month. These highlights do not include all the information needed to use WEGOVY safely and effectively. HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use WEGOVY® safely and effectively. In people who have kidney problems, diarrhea, nausea, and There may be new information. Novo Nordisk Pharmaceuticals Pty Ltd. Label elements Hazard pictogram(s) None required under U. 7 mg/ 0. Subscribe to updates; Contact us; Facebook (Twitter) Youtube; Instagram; LinkedIn; Scroll to ISI What is Wegovy ®?. Approval: 2017 See full prescribing information for complete boxed warning. PART I: HEALTH PROFESSIONAL INFORMATION . Wegovy ® works by acting on receptors in the brain that control your appetite, causing you to feel fuller and less hungry and experience less craving for food Weight Management,Adults,Wegovy is indicated as an adjunct to a reduced-energy diet and increased physical activity for chronic weight management (including weight loss and weight maintenance) in adults with an initial Body Mass Index (BMI) of,Equal to or greater than 30 kg/m2 (obesity), or,Equal to or greater than 27 kg/m2 to less than 30 kg This leaflet provides important information about using Wegovy® FlexTouch®. 28 MB] Device/Product Name. Prescribing Information Sheet, November 2020 This document provides general prescribing information on the use of Semaglutide. 7 mg FlexTouch ® solution for injection in pre-filled pen Highlights of the Article. Users This guide will help you: Learn how to use your pen Understand the dosing schedule Know what to expect Access support and savings Your next step begins here These highlights do not include all the information needed to use WEGOVY safely and effectively. Evaluation commenced. WEGOVY® (semaglutide) injection, for subcutaneous use Initial U. Keep this Discover information, education and resources for Wegovy® (semaglutide 2. Ministry of Health - Pharmaceutical, Laboratory & Blood Services Division Subject: Information sheet for public input into B. See full prescribing information for OZEMPIC. If needed, however, Wegovy ® can be kept outside of the refrigerator between 46°F to 86°F for These highlights do not include all the information needed to use WEGOVY safely and effectively. 4 mg (recommended) or 1. 02 KB] Attachment Product Information for Wegovy [Word, 903. 5 mg, 1 mg, or 2 mg is an injectable prescription medicine used:. This dose has shown efficacy in clinical trials and is the recommended maintenance dose per the prescribing information. Please click here for Prescribing Information, including Medication Guide. Once-weekly semaglutide in adults with overweight or obesity. If patients do not tolerate the maintenance 2. All medicines A-Z. txt) or read online for free. AU24NNM00004 | July 2024. UK24SEMO00130 November 2024 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use WEGOVY® safely and effectively. Scroll to ISI What is Ozempic ®?. PharmaCare Drug Information Sheet for semaglutide (Wegovy) Author: B. Novo Nordisk told Atlanta News First Investigates, “Although Wegovy and Ozempic® both contain semaglutide, they are different products with different Wegovy ® comes in 5 different dose strengths, which are injected under the skin. 5 mg FlexTouch® solution for injection in pre-filled pen . This medicine is subject to additional monitoring. RYBELSUS (semaglutide) tablets, for oral use Initial U. See full prescribing information for OZEMPIC ®. What is Wegovy™? Wegovy™ (semaglutide) injection 2. Lisa: All my life, my health care providers told me I needed to lose weight. Wegovy ® is similar to a natural hormone called glucagon-like peptide-1 (GLP-1) that is released from the intestine after a meal. In patients with type 2 diabetes, monitor blood glucose prior to starting and during WEGOVY treatment (2. Decision date. Active ingredients. 4 mg once weekly on the risk of major cardiovascular events such as death, heart attack, or stroke was studied in adults with known heart disease and either obesity or overweight compared with those on placebo (an inactive injection). 1 INDICATIONS AND USAGE WEGOVY is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of [see Dosage and Administration (2. Subscribe to updates; Contact us; Facebook (Twitter) Youtube Wegovy (semaglutide) injection 2. This Vaccine Information Fact Sheet contains information to help you understand the risks and benefits of COMIRNATY (COVID-19 Vaccine, mRNA),the Pfizer-BioNTech COVID-19 Vaccine, and the Pfizer-BioNTech COVID-19 Vaccine, Bivalent, which you may receive because there is currently a pandemic of COVID-19. (Wegovy). 5 mg, 1 mg, 1. Wilding JP, Batterham R, Calanna S, et al. 2. • Important Safety Information. Novo Nordisk Inc. 5 mg, and 1 mg new safety information. In studies, Zepbound has led to a 21% weight loss in adults using the highest dose, while Wegovy has led to about a 15% weight loss. Refer to FDA-approved Prescribing Information for final marketed products with regard to special storage, handling and administration requirements in the clinical setting. Search emc: Enter medicine name or company To ensure safe and effective use, emc and the pharmaceutical companies who provide information to this site, encourage reporting of suspected side effects to medicines, vaccines and medical device In studies with mice and rats, semaglutide (the active ingredient in Wegovy® and Ozempic®) caused thyroid tumors, including thyroid cancer. rotate) the site of injection for each administration. 8 months). 5 mg • In your third month, increase your weekly dose to 1 mg • In your fourth month, increase your weekly dose to 1. 3% of patients treated with Wegovy ® vs 1. Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight (BMI ≥ 27 kg/m 2). 4 mg is an injectable prescription medicine used for adults with obesity (BMI ≥30) or overweight (excess weight) (BMI ≥27) who also Wegovy® (semaglutide) injection 2. 7 mg and 2. [1-2] Semaglutide was initially approved as a treatment for type 2 diabetes, but studies have found that GLP-1 drugs At PrintFriendly. 5 MG/DOSE); Ozempic (1 MG/DOSE); Ozempic (2 MG/DOSE); Rybelsus; Wegovy Brand Names: Canada Ozempic, Mounjaro, Wegovy and Zepbound can all lead to long-term weight loss, but only Wegovy and Zepbound are approved by the FDA for this use. This comprehensive guide provides important information you need to know about prescribing Wegovy ®. 7 mg solution for injection See full prescribing information for WEGOVY. MOUNJARO® (tirzepatide) Injection, for subcutaneous use Initial U. The healthcare professional area contains promotional content and includes links to the prescribing information and adverse event reporting information. When you join WeGoTogether ®, you can be paired with a Health Coach who is dedicated to supporting your progress through calls, texts, and emails. The 0. Semaglutide. 5 September 2024. Click here for Prescribing Information, including Boxed Warning, for Wegovy™. You should also speak to your doctor or pharmacist if you would like further information or if you have any concerns or questions about using Wegovy® FlexTouch®. wegovy works by acting on receptors in the brain that control your appetite, causing you to feel fuller and less hungry and experience The Wegovy ® starting dose is 0. It is now 43 pages. Read Important Safety and Prescribing Info, including Boxed Warning. • • RECENT MAJOR Narrator: Lisa is a patient ambassador for Novo Nordisk and has been compensated for her participation in this video. and it is advisable to check with local pharmacies or healthcare providers for accurate pricing information. 75 mL 0169-4525-14 0169-4505-14 These highlights do not include all the information needed to use MOUNJARO safely and effectively. Ozempic ® (semaglutide) injection 0. Currently Wegovy ® (semaglutide) is available to patients 12 years of age and above. 4 mg Prescribing Information For more information about the dose escalation schedule for Wegovy ®, please see the Prescribing Information. Wegovy Injections are similar to Ozempic injections except that the dose of Semaglutide administered is high when Wegovy is used. OZEMPIC® (semaglutide) injection, for subcutaneous use Initial U. Kushner RF, Calanna S, Davies M, et al. Wegovy, a glucagon-like peptide-1 (GLP-1) receptor agonist, works by mimicking natural hormones that regulate appetite and digestion, making it a For complete instructions with diagrams on how to use Wegovy, see Instructions for Wegovy Use. You should store Wegovy ® in the refrigerator. The WEGOVY pen is for subcutaneous (under the skin) use only. Prescribing Strength NDC Days Supply Dispense Quantity Recommended SIG 0. Cancel Contact us. Obesity. 1 INDICATIONS . 25 mg injected subcutaneously once-weekly and follow the dose escalation schedule below to minimize gastrointestinal adverse reactions. Important Safety Information What is the most important information I should know about Wegovy ®? Wegovy B. Package leaflet: Information for the patient . Wegovy ® 0. • • RECENT MAJOR Administer WEGOVY once weekly as an adjunct to diet and increased physical activity, on the same day each week, at any time of day, with or without meals (2. Brand Names: US Ozempic (0. Little or no specific monitoring required. It belongs to a group of drugs that copy a hormone in your body to help control appetite and how much food you eat. 5% of patients who received placebo discontinued treatment as a result of gastrointestinal adverse events; Mean increases in resting heart rate of 1. WEGOVY (semaglutide) injection, for subcutaneous use Initial U. Prescribing Information. 4 mg is an injectable prescription medicine used with a reduced calorie diet and increased physical activity:. What is the most important information I HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use OZEMPIC® safely and effectively. Wegovy® 0. Scroll to ISI What is Wegovy ®?. The starting dose is 0. S. See full prescribing information for Aranesp. Approval: 2017 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use WEGOVY® safely and effectively. mhg eblfpk bhzim oyszzq lgsu txmbsr twbck mvmpangi uexvfv jgzau